NCT00329095

Brief Summary

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Dec 2005

Shorter than P25 for phase_4

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2005

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2006

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 19, 2006

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 24, 2006

Completed
Last Updated

May 24, 2006

Status Verified

May 1, 2006

First QC Date

May 19, 2006

Last Update Submit

May 22, 2006

Conditions

GlaucomaOcular Hypertension

Keywords

GlaucomaCompliance

Outcome Measures

Primary Outcomes (1)

  • Compliance.

Interventions

travoprost, latanoprost, or bimatoprostDRUG
Additional ocular hypotensive medicationDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Currently using one or two topical ocular hypotensive medications

You may not qualify if:

  • Hypersensitivity to any component of medication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007 Oct;144(4):533-40. doi: 10.1016/j.ajo.2007.06.012. Epub 2007 Aug 8.

    PMID: 17686450DERIVED

MeSH Terms

Conditions

GlaucomaOcular HypertensionPatient Compliance

Interventions

TravoprostLatanoprostBimatoprost

Condition Hierarchy (Ancestors)

Eye DiseasesPatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Intervention Hierarchy (Ancestors)

CloprostenolProstaglandins F, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological FactorsAmidesOrganic Chemicals

Study Officials

  • Alan L. Robin, MD

    Alan L. Robin, M.D.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
INDIV

Study Record Dates

First Submitted

May 19, 2006

First Posted

May 24, 2006

Study Start

December 1, 2005

Study Completion

April 1, 2006

Last Updated

May 24, 2006

Record last verified: 2006-05